Gyre Therapeutics (GYRE) 10-Q2022 Q2 Quarterly report

Content analysis

Filed: 15 Aug 22, 4:02pm

Date: August 15, 2022

/s/ Seline Miller

Seline Miller

Interim Chief Financial Officer
(Interim Financial and Principal Accounting Officer)

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. sophomore Avg

New words: adjusted, al, alleged, alleging, assumed, average, beneficially, captioned, carryforward, Ch, Chancery, Code, Copia, court, declaratory, Del, Delaware, denied, denominator, disposal, disposition, dividend, dividing, Dren, duty, fiduciary, forgive, furniture, goal, harboring, hearing, hold, immunotunetm, indefinitely, indemnification, injunctive, ISTH, judgement, lab, law, lawsuit, logistical, London, merit, monetary, motion, multiplying, NaN, NOL, ownership, parallel, point, protunetm, quickly, rendered, resolve, satisfaction, sequence, settlement, Society, sought, tax, taxable, traditionally, understood, unspecified, unused, Vertex, weighted, winding

Removed: aberrant, absence, achieve, activation, actively, administration, antibiotic, arrangement, atypical, autoimmune, bacteria, bioavailability, biological, blood, brain, broader, capable, chronic, circulating, complex, converted, cord, deficient, degrade, degrader, demonstrated, discretion, dosed, downstream, duration, dysregulated, encapsulated, endpoint, enroll, enrolling, extended, eye, favorable, frequently, functional, genetic, heart, Hemolytic, high, hyperactive, immune, ImmunoTUNE, impairment, improved, inclusion, increased, industry, inflammation, inflammatory, inhibiting, inhibitor, intended, invasive, key, large, lead, level, licensed, life, lifelong, main, maintaining, measurement, Membranoproliferative, merger, modified, objective, ocular, pegylated, pipeline, population, potency, potent, preferred, prevalence, private, profile, progression, protein, ProTUNE, quality, recurrent, reducing, regulation, regulator, replace, replacement, retrospective, role, safe, scope, serum, significantly, small, specific, specificity, spinal, supportable, Syndrome, system, systemic, Targacept, targeted, targeting, therapeutic, today, treated, uniquely, upstream, Uremic, variant, version, vision, wholly

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

GYRE similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.2

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report on Form 10-Q of Catalyst Biosciences, Inc. (the “Company”) for the period ended June 30, 2022 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Seline Miller, hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge:

(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.